Acridone derivatives are selective inhibitors of HIV-1 replication in chronically infected cells

Antiviral Research

Volumn 43, Issue 3, 1999, Pages 189-199

  Fujiwara, Masatoshi ^a,e   Okamoto, Mika ^b   Okamoto, Masayuki ^a   Watanabe, Mitsuaki ^c   Machida, Haruhiko ^d   Shigeta, Shiro ^e   Konno, Kenji ^a   Yokota, Tomoyuki ^a   Baba, Masanori ^b  

^a Rational Drug Design Laboratories   (Japan)

^b Ctr Chron Viral Dis Fac M   (Japan)

^c NAGASAKI UNIVERSITY   (Japan)

^d YAMASA CORPORATION   (Japan)

^e FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Acridone; Chronic infection; HIV 1; PKC; Transcription

Indexed keywords

9,10 DIHYDRO 1 HYDROXY 10 METHYLACRID 9 ONE; ACRIDONE DERIVATIVE; ANTIGEN P24; ANTIVIRUS AGENT; HA 100; PHORBOL 13 ACETATE 12 MYRISTATE; PROTEIN KINASE C; PROTEIN KINASE C INHIBITOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CELL LINE; CONTROLLED STUDY; DOSE RESPONSE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; PRIORITY JOURNAL; VIRUS ACTIVATION; VIRUS REPLICATION;

EID: 0032881392     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-3542(99)00045-5     Document Type: Article

References (41)

1. Acres R.B., Conlon P.J., Mochizuki Y., Gallis B. Rapid phosphorylation and modulation of the T4 antigen on cloned helper T-cells induced by phorbol myristate acetate or antigen. J. Biol. Chem. 261:1986;16210-16214.
2. Baba M. Cellular factors as alternative targets for inhibition of HIV-1. Antiviral Res. 33:1997;141-152.
3. Baba M., Okamoto M., Makino M., Kimura Y., Ikeuchi T., Sakaguchi T., Okamoto T. Potent and selective inhibition of human immunodeficiency virus type 1 transcription by piperazinyloxoquinoline derivatives. Antimicrob. Agents Chemother. 41:1997;1250-1255.
4. Baba M., Okamoto M., Kawamura M., Makino M., Higashida T., Takashi T., Kimura Y., Ikeuchi T., Tetsuka T., Okamoto T. Inhibition of human immunodeficiency virus type 1 replication and cytokine production by fluoroquinoline derivatives. Mol. Pharmacol. 53:1998;1097-1103.
5. + cell model of chronic infection. J. Virol. 65:1991;4645-4653.
6. Butera S.T., Roberts B.D., Lam L., Hodge T., Folks T.M. Human immunodeficiency virus type 1 RNA expression by four chronically infected cell lines indicates multiple mechanisms of latency. J. Virol. 68:1994;2726-2730.
7. Butera S.T., Roberts B.D., Critchfield J.W., Fang G., McQuade T, Gracheck S.J., Folks T.M. Compounds that target novel cellular components involved in HIV-1 transcription. Mol. Med. 1:1995;758-767.
8. Castagna M., Takai Y., Kaibuchi K., Sano K., Kikkawa U., Nishizuka Y. Direct activation of calcium-activated, phospholipid-dependent protein kinase by tumor-promoting phorbol esters. J. Biol. Chem. 257:1982;7847-7851.
9. Clouse K.A., Powell D., Washington I., Poli G., Strebel K., Farrar W., Barstad P., Kovacs J., Fauci A.S., Folks T.M. Monokine regulation of human immunodeficiency virus-1 expression in a chronically infected human T-cell clone. J. Immunol. 142:1989;431-438.
10. Critchfield J.W., Butera S.T., Folks T.M. Inhibition of HIV activation in latently infected cells by flavonoid compounds. AIDS Res. Hum. Retroviruses. 12:1996;39-46.
11. Critchfield J.W., Coligan J.E., Folks T.M., Butera S.T. Casein kinase II is a selective target of HIV-1 transcriptional inhibitors. Proc. Natl. Acad. Sci. USA. 94:1997;6110-6115.
12. De Clercq E. Antiviral therapy for human immunodeficiency virus infections. Clin. Microbiol. Rev. 8:1995;200-239.
13. Duh E.J., Maury W.J., Folks T.M., Fauci A.S., Rabson A.B. Tumor necrosis factor-α activates human immunodeficiency virus type 1 through induction of nuclear factor binding to the NF-κB sites in the long terminal repeat. Proc. Natl. Acad. Sci. USA. 86:1989;5974-5978.
14. Feorino P.M., Butera S.T., Folks T.M., Schinazi R.F. Prevention of activation of HIV-1 by antiviral agents in OM-10.1 cells. Antiviral Chem. Chemother. 4:1993;55-63.
15. Finzi D., Hermankova M., Pierson T., Carruth L.M., Buck C., Chaisson R.E., Quinn T.C., Chadwick K., Margolick J., Brookmeyer R., Gallant J., Markowitz M., Ho D.D., Richman D.D., Siliciano R.F. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science. 278:1997;1295-1300.
16. Fujiwara M., Ijichi K., Tokuhisa K., Katsuura K., Wang G.-Y.-S., Uemura D., Shigeta S., Konno K., Yokota T., Baba M. Ingenol derivatives are highly potent and selective inhibitors of HIV replication in vitro. Antiviral Chem. Chemother. 7:1996;230-236.
17. Folks T.M., Justement J., Kinter A., Schnittman S., Orenstein J., Poli G., Fauci A.S. Characterization of a promonocyte clone chronically infected with HIV and inducible by 13-phorbol-12-myristate acetate. J. Immunol. 140:1988;1117-1122.
18. Gendelman H.E., Phelps W., Feigenbaum W., Ostrove J.M., Adachi A., Howley P.M., Khoury G., Ginsberg H.S., Martin M.A. Transactivation of the human immunodeficiency virus long terminal repeat sequence by DNA viruses. Proc. Natl. Acad. Sci. USA. 83:1986;9759-9763.
19. Hagiwara M., Inagaki M., Watanabe M., Ito M., Onoda K., Tanaka T., Hidaka H. Selective modulation of calcium-dependent myosin phosphorylation by novel protein kinase inhibitors, isoquinolinesulfonamide derivatives. Mol. Pharmacol. 32:1987;7-12.
20. Ho D.D., Neumann A.U., Perelson A.S., Chen W., Leonard J.M., Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature. 373:1995;123-126.
21. Kikkawa U., Takai Y., Minakuchi R., Inohara S., Nishizuka Y. Calcium-activated, phospholipid-dependent protein kinase from rat brain. J. Biol. Chem. 257:1982;13341-13348.
22. Kikukawa R., Koyanagi Y., Harada S., Kobayashi N., Hatanaka M., Yamamoto N. Differential susceptibility to the acquired immunodeficiency syndrome retrovirus in cloned cells of human leukemic T-cell line Molt-4. J. Virol. 57:1986;1159-1162.
23. Kinter A.L., Poli G., Maury W., Folks T.M., Fauci A.S. Direct and cytokine-mediated activation of protein kinase C induces human immunodeficiency virus expression in chronically infected promonocytic cells. J. Virol. 64:1990;4306-4312.
24. Kopp E., Ghosh S. Inhibition of NF-κB by sodium salicylate and aspirin. Science. 265:1994;956-959.
25. Kramer M.J., Cleeland R., Grunberg E. Antiviral activity of 10-carboxymethyl-9-acridanone. Antimicrob. Agents Chemother. 9:1976;233-238.
26. Mancebo H.S.Y., Lee G., Flygare J., Tomassini J., Luu P., Zhu Y., Peng J., Blau C., Hazuda D., Price D., Flores O. P-TEFb kinase is required for HIV Tat transcriptional activation in vivo and in vitro. Genes Dev. 11:1997;2633-2644.
27. Miyoshi I., Taguchi H., Kubonishi I., Yoshimoto S., Ohtsuki Y., Shiraishi Y., Akagi T. Type C virus-producing cell lines derived from adult T-cell leukemia. Gann Monogr. 28:1982;219-228.
28. Moreira A.L., Sampaio E.P., Zmuidzinas A., Frindt P., Smith K.A., Kaplan G. Thalidomide exerts its inhibitory action on tumor necrosis factor a by enhancing mRNA degradation. J. Exp. Med. 177:1993;1675-1680.
29. Okamoto M., Ono M., Baba M. Potent inhibition of HIV type 1 replication by an antiinflammatory alkaloid, cepharanthine, in chronically infected monocytic cells. AIDS Res. Hum. Retrovir. 14:1998;1239-1245.
30. Pätzold S., Schneider J., Rudolph C., Marmé D., Schächtele C. Novel indolocarbazole protein kinase C inhibitors prevent reactivation of HIV-1 in latently infected cells. Antiviral Res. 22:1993;273-283.
31. Pauwels R., Balzarini J., Baba M., Snoeck R., Schols D., Herdewijn P., Desmyter J., De Clercq E. Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J. Virol. Methods. 20:1988;309-321.
32. Qatsha K.A., Rudolph C., Marme D., Schächtele C., May W.S. Gö 6976, a selective inhibitor of protein kinase C, is a potent antagonist of human immunodeficiency virus 1 induction from latent/low-level-producing reservoir cells in vitro. Proc. Natl. Acad. Sci. USA. 90:1993;4674-4678.
33. Roederer M., Staal F.J.T., Raju P.A., Ela S.W., Herzenberg L.A., Herzenberg L.A. Cytokine-stimulated human immunodeficiency virus replication is inhibited by N-acetyl-l-cysteine. Proc. Natl. Acad. Sci. USA. 87:1990;4884-4888.
34. Roederer M., Raju P.A., Staal F.J.T., Herzenberg L.A., Herzenberg L.A. N-Acetylcysteine inhibits latent HIV expression in chronically infected cells. AIDS Res. Hum. Retroviruses. 7:1991;563-567.
35. Schreiber E., Matthias P., Müller M., Schaffner W. Rapid detection of octamer binding proteins with 'mini-extracts', prepared from a small number of cells. Nucleic Acids Res. 17:1989;6419.
36. Schütze S., Nottrott S., Pfïzenmaier K., Krönke M. Tumor necrosis factor signal transduction. Cell-type-specific activation and translocation of protein kinase C. J. Immunol. 144:1990;2604-2608.
37. Turpin J.A., Buckheit Jr R.W., Derse D., Hollingshead M., Williamson K., Palamone C., Osterling M.C., Hill S.A., Graham L., Schaeffer C.A., Bu M., Huang M., Cholody W.M., Michejda C.J., Rice W.G. Inhibition of acute-, latent-, and chronic-phase human immunodeficiency virus type 1 (HIV-1) replication by a bistriazoloacridone analog that selectively inhibits HIV-1 transcription. Antimicrob. Agents Chemother. 42:1998;487-494.
38. Yamamoto N., Furukawa H., Ito Y., Yoshida S., Maeno K., Nishiyama Y. Anti-herpesvirus activity of citrusinine-I, a new acridone alkaloid, and related compounds. Antiviral Res. 12:1989;21-36.
39. Wei P., Garber M.E., Fang S.-M., Fischer W.H., Jones K.A. A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA. Cell. 92:1998;451-462.
40. Wong J.K., Hezareh M., Günthard H.F., Havlir D.V., Ignacio C.C., Spina C.A., Richman D.D. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science. 278:1997;1291-1295.
41. Zhou Q., Chen D., Pierstorff E., Luo K.X. Transcription elongation factor P-TEFb mediates Tat activation of HIV-1 transcription at multiple stages. EMBO J. 17:1998;3681-3691.